Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
Status:
Completed
Trial end date:
2016-07-25
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group,
dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release
Capsule) in children 6-12 years of age with ADHD.